JP2013526840A - 組み換えブチリルコリンエステラーゼおよびその切断型 - Google Patents
組み換えブチリルコリンエステラーゼおよびその切断型 Download PDFInfo
- Publication number
- JP2013526840A JP2013526840A JP2012545932A JP2012545932A JP2013526840A JP 2013526840 A JP2013526840 A JP 2013526840A JP 2012545932 A JP2012545932 A JP 2012545932A JP 2012545932 A JP2012545932 A JP 2012545932A JP 2013526840 A JP2013526840 A JP 2013526840A
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- bche
- isolated nucleic
- polypeptide
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
本出願は、2009年12月21日に出願された米国仮出願第61/284,444号の優先権を主張し、その開示内容全体が参考として本明細書に取り入れられる。
同一性百分率=100[1−(C/R)]
Claims (40)
- BChE酵素活性を有するポリペプチドをコード化する単離された核酸であって、前記核酸のコード領域におけるグアニンおよびシトシン(G+C)ヌクレオチドの百分率が40%を超えるが80%を超えない単離された核酸。
- 前記核酸のコード領域におけるグアニンおよびシトシン(G+C)ヌクレオチドの百分率が45%を超えるが80%を超えない、請求項1に記載の単離された核酸。
- 前記核酸のコード領域におけるグアニンおよびシトシン(G+C)ヌクレオチドの百分率が50%を超えるが80%を超えない、請求項1に記載の単離された核酸。
- 前記核酸のコード領域におけるグアニンおよびシトシン(G+C)ヌクレオチドの百分率が55%を超えるが80%を超えない、請求項1に記載の単離された核酸。
- 前記核酸のコード領域におけるグアニンおよびシトシン(G+C)ヌクレオチドの百分率が60%を超えるが80%を超えない、請求項1に記載の単離された核酸。
- 前記核酸のコード領域におけるグアニンおよびシトシン(G+C)ヌクレオチドの百分率が少なくとも60%であるが80%を超えない、請求項1に記載の単離された核酸。
- 前記核酸が内部TATAボックスを含まないまたはコード化しない、請求項1に記載の単離された核酸。
- 前記核酸が前記ポリペプチド上に一以上のシアル化部位をコード化しない、請求項1に記載の単離された核酸。
- 前記核酸が内部リボソーム進入部位を含まないまたはコード化しない、請求項1に記載の単離された核酸。
- 前記核酸がスプライス供与または受容部位を含まないまたはコード化しない、請求項1に記載の単離された核酸。
- 前記核酸が開始部位の上流に少なくとも一つのKozak配列を含むまたはコード化する、請求項1に記載の単離された核酸。
- 前記核酸の配列はコドン適応指標(CAI)が少なくとも0.7である、請求項1に記載の単離された核酸。
- 前記核酸はCAIが少なくとも0.8である、請求項1に記載の単離された核酸。
- 前記核酸はCAIが少なくとも0.9である、請求項1に記載の単離された核酸。
- 前記核酸はCAIが少なくとも0.97である、請求項1に記載の単離された核酸。
- 前記核酸が配列番号1のヌクレオチド配列に少なくとも90%の同一性を有するヌクレオチド配列またはその相補体を含む、請求項1に記載の単離された核酸。
- 前記核酸が配列番号1のヌクレオチド配列に少なくとも95%の同一性を有するヌクレオチド配列またはその相補体を含む、請求項1に記載の単離された核酸。
- 前記核酸が配列番号1のヌクレオチド配列に少なくとも98%の同一性を有するヌクレオチド配列またはその相補体を含む、請求項1に記載の単離された核酸。
- 前記核酸が配列番号1のヌクレオチド配列またはその相補体を含む、請求項1に記載の単離された核酸。
- 前記BChEポリペプチドが配列番号2の22〜564番アミノ酸を含む、請求項1に記載の単離された核酸。
- 前記BChEポリペプチドが配列番号2におけるアミノ酸の数より少ないアミノ酸を含む、請求項1に記載の単離された核酸。
- 前記BChEポリペプチドが単量体のみを形成する、請求項1に記載の単離された核酸。
- 前記BChEがWATドメインの全体または一部を欠損している、請求項1に記載の単離された核酸。
- 請求項1に記載の核酸の単離されたフラグメントであって、BChE酵素活性を有するポリペプチドをコード化するフラグメント。
- 請求項1に記載の核酸を含んでなるベクター。
- 請求項25に記載のベクターを含んでなる組み換え細胞。
- BChE酵素活性を有するポリペプチドを調製する方法であって、請求項26に記載の細胞から前記ポリペプチドを発現させることを含んでなる方法。
- 前記細胞が哺乳動物細胞である、請求項26に記載の組み換え細胞。
- 前記細胞がヒト細胞である、請求項26に記載の組み換え細胞。
- 前記細胞がPer.C6細胞である、請求項26に記載の組み換え細胞。
- 前記ポリペプチドが配列番号2のアミノ酸配列を含む、請求項27に記載の方法。
- 前記ポリペプチドが単量体のみを形成する、請求項27に記載の方法。
- 前記ポリペプチドがWATドメインの全体または一部を含まない、請求項27に記載の方法。
- 前記ポリペプチドがWATドメインを含まない、請求項33に記載の方法。
- 前記ポリペプチドが配列番号7のアミノ酸配列の全体または一部を含まない、請求項27に記載の方法。
- 前記ポリペプチドが配列番号2の22〜564番アミノ酸を含む、請求項27に記載の方法。
- 前記ポリペプチドが配列番号2の22〜564番アミノ酸からなる、請求項27に記載の方法。
- 前記核酸がDNAまたはその相補体である、請求項1に記載の単離された核酸。
- 前記DNAがcDNAまたはその相補体である、請求項38に記載の単離された核酸。
- 前記核酸がRNAである、請求項1に記載の単離された核酸。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28444409P | 2009-12-21 | 2009-12-21 | |
US61/284,444 | 2009-12-21 | ||
PCT/US2010/003225 WO2011084145A2 (en) | 2009-12-21 | 2010-12-21 | Recombinant butyrylcholinesterases and truncates thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013526840A true JP2013526840A (ja) | 2013-06-27 |
JP2013526840A5 JP2013526840A5 (ja) | 2014-02-13 |
Family
ID=44306009
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012545932A Ceased JP2013526840A (ja) | 2009-12-21 | 2010-12-21 | 組み換えブチリルコリンエステラーゼおよびその切断型 |
Country Status (6)
Country | Link |
---|---|
US (2) | US8729245B2 (ja) |
EP (1) | EP2516664B1 (ja) |
JP (1) | JP2013526840A (ja) |
AU (1) | AU2010340358B2 (ja) |
CA (1) | CA2784861A1 (ja) |
WO (1) | WO2011084145A2 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20170138390A (ko) * | 2015-04-24 | 2017-12-15 | 훼링 비.브이. | 고나도트로핀 생산 방법 |
KR20180077275A (ko) * | 2015-11-05 | 2018-07-06 | 뱀부 테라퓨틱스 인코포레이티드 | 유전자 치료를 위한 변형된 프리드라이히 운동실조증 유전자 및 벡터 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2784861A1 (en) | 2009-12-21 | 2011-07-14 | Pharmathene, Inc. | Recombinant butyrylcholinesterases and truncates thereof |
US9688970B2 (en) | 2013-10-01 | 2017-06-27 | Kentucky Bioprocessing, Inc. | Plant-based recombinant butyrylcholinesterase production methods |
CN108486114A (zh) * | 2018-04-18 | 2018-09-04 | 西南大学 | 实现两个基因等量表达的基因元件及表达载体 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009024567A1 (en) * | 2007-08-20 | 2009-02-26 | Glaxo Group Limited | Production method |
WO2009046464A1 (en) * | 2007-10-05 | 2009-04-09 | Merial Limited | Articular cartilage gene therapy with recombinant vector encoding bmp-7 |
JP2009183295A (ja) * | 2001-10-11 | 2009-08-20 | Merck & Co Inc | C型肝炎ウイルスワクチン |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US6727405B1 (en) | 1986-04-09 | 2004-04-27 | Genzyme Corporation | Transgenic animals secreting desired proteins into milk |
US5215909A (en) | 1986-06-18 | 1993-06-01 | Yeda Research & Development Co., Ltd. | Human cholinesterase genes |
US5322775A (en) | 1986-06-30 | 1994-06-21 | Pharmaceutical Proteins Ltd. | Peptide production |
EP0832981A1 (en) | 1987-02-17 | 1998-04-01 | Pharming B.V. | DNA sequences to target proteins to the mammary gland for efficient secretion |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
IL89703A (en) | 1989-03-21 | 2001-10-31 | Yissum Res Dev Co | Polynucleotide encoding human acetylcholinesterase, vectors comprising said polynucleotide, cells transformed by said vectors, enzyme produced by said transformed cell, and uses thereof |
US5227301A (en) | 1989-11-03 | 1993-07-13 | The 501 Institution For The Advancement Of Learning (Mcgill University) | Immortalized bovine mannary epithelial cell line |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
US5831141A (en) | 1991-01-11 | 1998-11-03 | United States Of America As Represented By The Department Of Health And Human Services | Expression of a heterologous polypeptide in mammary tissue of transgenic non-human mammals using a long whey acidic protein promoter |
IL101600A (en) | 1992-04-15 | 2000-02-29 | Yissum Res Dev Co | Synthetic partially phosphorothioated antisense oligodeoxynucleotides and pharmaceutical compositions containing them |
US6110742A (en) | 1992-04-15 | 2000-08-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Synthetic antisense oligodeoxynucleotides targeted to AChE |
PT804070E (pt) | 1993-03-09 | 2000-11-30 | Genzyme Corp | Isolamento de componentes de interesse a partir do leite. |
US5610053A (en) | 1993-04-07 | 1997-03-11 | The United States Of America As Represented By The Department Of Health And Human Services | DNA sequence which acts as a chromatin insulator element to protect expressed genes from cis-acting regulatory sequences in mammalian cells |
DE4326665C2 (de) | 1993-08-09 | 1995-07-13 | Biotest Pharma Gmbh | Verfahren zur Sterilfiltration von Milch |
US6025183A (en) | 1994-02-28 | 2000-02-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Transgenic animal assay system for anti-cholinesterase substances |
US5932780A (en) | 1994-02-28 | 1999-08-03 | Yissum Research Development Company Of Hebrew University Of Jerusalem | Transgenic non-human animal assay system for anti-cholinesterase substances |
US6204431B1 (en) | 1994-03-09 | 2001-03-20 | Abbott Laboratories | Transgenic non-human mammals expressing heterologous glycosyltransferase DNA sequences produce oligosaccharides and glycoproteins in their milk |
US5807671A (en) | 1995-01-09 | 1998-09-15 | Yissum Research Development Company Of Hebrew University Of Jerusalem | Method of screening for genetic predisposition to anticholinesterase therapy |
US5780009A (en) | 1995-01-20 | 1998-07-14 | Nexia Biotechnologies, Inc. | Direct gene transfer into the ruminant mammary gland |
US6001625A (en) | 1995-05-19 | 1999-12-14 | The United States Of America As Represented By The Secretary Of The Army | Site-directed mutagenesis of esterases |
IL115873A0 (en) | 1995-11-03 | 1996-01-31 | Peri Dev Applic 1985 Ltd | Transgenic protein production |
US6326139B1 (en) | 1996-01-11 | 2001-12-04 | Yissum Research Development Company Of Hebrew University Of Jerusalem | Method of screening for genetic predisposition to anticholinesterase therapy |
US6268487B1 (en) | 1996-05-13 | 2001-07-31 | Genzyme Transgenics Corporation | Purification of biologically active peptides from milk |
US20020184655A1 (en) | 1997-12-01 | 2002-12-05 | Henryk Lubon | Methods for the degradation and detoxification of organic material using urine produced by transgenic animals and related transgenic animals and proteins |
US7157615B2 (en) | 1998-03-17 | 2007-01-02 | Nexia Biotechnologies, Inc. | Production of biofilaments in transgenic animals |
ATE253126T1 (de) | 1998-08-25 | 2003-11-15 | Univ Washington | Schnelle quantitative analyse von proteinen oder proteinfunktionen in komplexen gemischen |
EP1112353A2 (en) | 1998-09-16 | 2001-07-04 | Nexia Biotechnologies, Inc. | Recombinant protein production in urine |
US6580017B1 (en) | 1998-11-02 | 2003-06-17 | Genzyme Transgenics Corporation | Methods of reconstructed goat embryo transfer |
WO2000029608A1 (en) | 1998-11-13 | 2000-05-25 | New York University | Transgenic animals as urinary bioreactors for the production of protein in the urine, recombinant dna construct for kidney-specific expression, and method of using same |
EP1958503A3 (en) | 1999-01-06 | 2008-11-26 | Merrimack Pharmaceuticals, Inc. | Expression of secreted human alpha-fetoprotein in transgenic animals |
US7297680B2 (en) * | 1999-04-15 | 2007-11-20 | Crucell Holland B.V. | Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content |
EP1175453B1 (en) | 1999-04-26 | 2003-10-29 | U.S. Army Medical Research and Materiel Command | Differentially acting op detoxifying sponges |
IL131707A0 (en) | 1999-05-31 | 2001-03-19 | Yissum Res Dev Co | Acetylcholinesterase-derived peptides and uses thereof |
AU2001250856A1 (en) | 2000-03-17 | 2001-10-03 | Charles Arntzen | Expression of recombinant human acetylcholinesterase in transgenic plants |
AU2001259063A1 (en) | 2000-04-12 | 2001-10-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US6946134B1 (en) | 2000-04-12 | 2005-09-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US7070973B2 (en) | 2000-12-26 | 2006-07-04 | Board Of Regents Of The University Of Nebraska | Butyrylcholinesterase variants and methods of use |
IL142875A (en) | 2001-04-30 | 2009-08-03 | Avigdor Shafferman | PEG-linked cholinesterases for the detoxification of circulating organophosphorus |
OA13136A (en) | 2001-05-21 | 2006-12-13 | Nektar Therapeutics | Pulmonary administration of chemically modified insulin. |
AU2002365202A1 (en) * | 2001-11-09 | 2003-09-02 | Entremed, Inc. | Synthetic genes for malarial proteins and methods of use |
AU2002353374A1 (en) | 2001-12-21 | 2003-07-09 | Nexia Biotechnologies, Inc. | Production of butyrylcholinesterases in transgenic mammals |
MXPA05005996A (es) * | 2002-12-04 | 2006-04-18 | Applied Molecular Evolution | Variantes de butirilcolinesterasa que modifican la actividad de agentes quimioterapeuticos. |
CA2541473A1 (en) | 2003-10-10 | 2005-04-21 | Yissum Research Development Company Of The Hebrew University Of Jerusale M | Method and kit for assessing anxiety or disposition thereto in a subject |
EP1533619B1 (en) | 2003-11-20 | 2009-04-29 | F. Hoffmann-Roche AG | Specific markers for metabolic syndrome |
WO2005066337A2 (en) | 2004-01-09 | 2005-07-21 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compounds, pharmaceutical compositions and therapeutic methods of preventing and treating diseases and disorders associated with amyloid fibril formation |
WO2007011390A2 (en) | 2004-10-09 | 2007-01-25 | Government Of The United States As Represented By The Secretary Of The Army | Large-scale production of human serum butyrylcholinesterase as a bioscavenger |
US9062321B2 (en) | 2004-12-01 | 2015-06-23 | Arizona Board Of Regents On Behalf Of Arizona State University | Codon-optimized polynucleotides encoding human butyrylcholinesterase and plant expression systems therof |
WO2006063055A2 (en) | 2004-12-06 | 2006-06-15 | Bolder Biotechnology, Inc. | Enzyme conjugates for use as detoxifying agents |
IL169377A (en) | 2005-06-23 | 2012-09-24 | Avigdor Shafferman | Uniformly conjugated serine hydrolases |
EP2035561A1 (en) | 2006-06-29 | 2009-03-18 | DSMIP Assets B.V. | A method for achieving improved polypeptide expression |
JP2009545329A (ja) | 2006-08-04 | 2009-12-24 | ファーマシーネ,インコーポレイテッド | 長い半減期の組換え型ブチリルコリンエステラーゼ |
CA2784861A1 (en) | 2009-12-21 | 2011-07-14 | Pharmathene, Inc. | Recombinant butyrylcholinesterases and truncates thereof |
-
2010
- 2010-12-21 CA CA2784861A patent/CA2784861A1/en not_active Abandoned
- 2010-12-21 EP EP10842361.7A patent/EP2516664B1/en not_active Not-in-force
- 2010-12-21 JP JP2012545932A patent/JP2013526840A/ja not_active Ceased
- 2010-12-21 US US13/517,081 patent/US8729245B2/en active Active
- 2010-12-21 WO PCT/US2010/003225 patent/WO2011084145A2/en active Application Filing
- 2010-12-21 AU AU2010340358A patent/AU2010340358B2/en not_active Ceased
-
2014
- 2014-04-03 US US14/244,026 patent/US8952143B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009183295A (ja) * | 2001-10-11 | 2009-08-20 | Merck & Co Inc | C型肝炎ウイルスワクチン |
WO2009024567A1 (en) * | 2007-08-20 | 2009-02-26 | Glaxo Group Limited | Production method |
WO2009046464A1 (en) * | 2007-10-05 | 2009-04-09 | Merial Limited | Articular cartilage gene therapy with recombinant vector encoding bmp-7 |
Non-Patent Citations (3)
Title |
---|
JPN6015000169; Taylor,P.: '"Accession:M99492[gi:191579],Definition:Mouse butyrylcholinesterase mRNA, complete cds."' NCBI Entrez Nucleotide[online];30-NOV-2009 uploaded,NCBI * |
JPN6015000170; McTiernan,C.et al.: '"Accession:M16541[gi:1280204],Definition:Human butyrylcholinesterase, mRNA, complete cds."' NCBI Entrez Nucleotide[online];10-JUL-2009 uploaded,NCBI * |
JPN6015000173; Eur.J.Biochem.,2002,269(2),p.630-7 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20170138390A (ko) * | 2015-04-24 | 2017-12-15 | 훼링 비.브이. | 고나도트로핀 생산 방법 |
JP2018512885A (ja) * | 2015-04-24 | 2018-05-24 | フェリング ベスローテン フェンノートシャップ | ゴナドトロピンの製造方法 |
KR102658666B1 (ko) * | 2015-04-24 | 2024-04-17 | 훼링 비.브이. | 고나도트로핀 생산 방법 |
KR20180077275A (ko) * | 2015-11-05 | 2018-07-06 | 뱀부 테라퓨틱스 인코포레이티드 | 유전자 치료를 위한 변형된 프리드라이히 운동실조증 유전자 및 벡터 |
JP2018531609A (ja) * | 2015-11-05 | 2018-11-01 | バンブー セラペウティクス インク | 遺伝子療法のための、改変されたフリードライヒ運動失調症遺伝子およびベクター |
KR102200642B1 (ko) | 2015-11-05 | 2021-01-12 | 뱀부 테라퓨틱스 인코포레이티드 | 유전자 치료를 위한 변형된 프리드라이히 운동실조증 유전자 및 벡터 |
JP2021019591A (ja) * | 2015-11-05 | 2021-02-18 | バンブー セラペウティクス インク | 遺伝子療法のための、改変されたフリードライヒ運動失調症遺伝子およびベクター |
Also Published As
Publication number | Publication date |
---|---|
WO2011084145A2 (en) | 2011-07-14 |
WO2011084145A3 (en) | 2013-05-30 |
US20140220658A1 (en) | 2014-08-07 |
AU2010340358A1 (en) | 2012-07-19 |
US20120252094A1 (en) | 2012-10-04 |
CA2784861A1 (en) | 2011-07-14 |
EP2516664A4 (en) | 2013-11-13 |
EP2516664A1 (en) | 2012-10-31 |
AU2010340358B2 (en) | 2014-07-24 |
EP2516664B1 (en) | 2015-07-22 |
US8729245B2 (en) | 2014-05-20 |
US8952143B2 (en) | 2015-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
McBlane et al. | Cleavage at a V (D) J recombination signal requires only RAG1 and RAG2 proteins and occurs in two steps | |
KR102474010B1 (ko) | 유전적 병태를 치료하기 위한 방법 및 조성물 | |
EP2449135B1 (en) | Rapid screening of biologically active nucleases and isolation of nuclease-modified cells | |
EP2527435B1 (en) | Methods and compositions for inactivating alpha 1,6 fucosyltransferase (FUT 8) gene expression | |
US8952143B2 (en) | Recombinant butyrylcholinesterases and truncates thereof | |
JP2022097653A (ja) | ヒトα-ガラクトシダーゼバリアント | |
EP3262168B1 (en) | Host cell protein modification | |
JPH09509851A (ja) | ヒトホスホジエステラーゼ型ivc、並びにその生産および使用 | |
JP2022522112A (ja) | ヒト化細胞系 | |
KR20230005865A (ko) | 전위-기반 요법 | |
Ceylan et al. | Cloning, expression, and characterization of human brain acetylcholinesterase in Escherichia coli using a SUMO fusion tag | |
AU2011298451B2 (en) | Use of a HSPC117 molecule as RNA ligase | |
US20210108188A1 (en) | Non-covalent systems and methods for dna editing | |
PL240561B1 (pl) | Wektory DNA zdolne do transformacji i integracji z chromosomem Leishmania tarentolae zawierające gen kodujący butyrylocholinoesterazę BChE | |
US20230323335A1 (en) | Miniaturized cytidine deaminase-containing complex for modifying double-stranded dna | |
KR101906442B1 (ko) | 피스코미트렐라 파텐스에서 프롤릴-4-히드록실라아제의 변형된 발현 | |
RU2732795C1 (ru) | Рекомбинантный слитый белок | |
RU2820830C2 (ru) | Линия клеток, содержащая новый маркер отбора, и ее применение для продуцирования белков | |
KR20190088483A (ko) | 신규 엔도-β-N-아세틸글루코사미니다아제 | |
JP5441022B2 (ja) | DNA結合能をもつ高等植物のSpo11類縁タンパク質の調製法 | |
KR20160089082A (ko) | Mus81-Eme1-DNA 복합체의 3차원 결정구조 및 결정화 방법 | |
CN115279419A (zh) | 用于基因组工程的组合物和方法 | |
JP2003199588A (ja) | 新規ユビキチン特異プロテアーゼ | |
KR20150145865A (ko) | Talen을 이용하여 grk5 넉아웃 마우스를 제조하는 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131219 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20131219 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20141210 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150113 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150409 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150512 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150615 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20151020 |
|
A045 | Written measure of dismissal of application [lapsed due to lack of payment] |
Free format text: JAPANESE INTERMEDIATE CODE: A045 Effective date: 20160223 |